Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).
Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.
A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.
Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
- Conditions
- Childhood Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent DiseaseAccelerated Phase of DiseaseChronic Phase of Disease
- Interventions
- Drug: Fludarabine PhosphateRadiation: Total-Body IrradiationProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationDrug: CyclosporineDrug: Mycophenolate MofetilBiological: Therapeutic Allogeneic LymphocytesOther: Laboratory Biomarker Analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00003145
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Stanford University Hospitals and Clinics, Stanford, California, United States
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmLeukemiaMyelodysplastic SyndromesLymphomaMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00044954
- Locations
- 🇺🇸
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, United States
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Childhood Myelodysplastic SyndromesChildhood Nasal Type Extranodal NK/T-cell LymphomaAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionAcute Undifferentiated Leukemia
- Interventions
- Drug: fludarabine phosphateRadiation: total-body irradiationProcedure: peripheral blood stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationDrug: cyclosporineDrug: mycophenolate mofetilOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT00014235
- Locations
- 🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission
- Conditions
- Adult Acute Lymphoblastic Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in RemissionRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationBiological: donor lymphocytesDrug: cyclosporineRadiation: total-body irradiationDrug: fludarabine phosphateDrug: mycophenolate mofetilOther: laboratory biomarker analysisProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-12-07
- Lead Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Target Recruit Count
- 30
- Registration Number
- NCT00031655
- Locations
- 🇺🇸
Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Oregon Health and Sciences University, Portland, Oregon, United States
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
- Conditions
- Myelodysplastic SyndromeMyeloproliferative DisordersAcute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaChronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Target Recruit Count
- 202
- Registration Number
- NCT00003838
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Biological: alemtuzumabDrug: cyclosporineDrug: fludarabine phosphateDrug: melphalanProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00027560
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00049634
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
- Conditions
- Recurrent Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- Drug: fludarabine phosphateRadiation: total-body irradiationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationDrug: cyclosporineDrug: mycophenolate mofetilProcedure: peripheral blood stem cell transplantationBiological: therapeutic allogeneic lymphocytesOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00005851
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT00008307
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
- Conditions
- Graft Versus Host DiseaseLeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT00003335
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.